These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12060479)

  • 1. Instrumental evaluation of retinoid-induced skin irritation.
    Stücker M; Hoffmann M; Altmeyer P
    Skin Res Technol; 2002 May; 8(2):133-40. PubMed ID: 12060479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
    Guenther LC; Poulin YP; Pariser DM
    Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study.
    Poulin YP
    Cutis; 1999 Jan; 63(1):41-8. PubMed ID: 9951595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing treatment with topical tazarotene.
    Guenther LC
    Am J Clin Dermatol; 2003; 4(3):197-202. PubMed ID: 12627995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis.
    Koo J; Behnam SE; Behnam SM
    Expert Opin Pharmacother; 2003 Dec; 4(12):2347-54. PubMed ID: 14640932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis.
    Kaur I; Dogra S; Jain R; Kumar B
    Indian J Dermatol Venereol Leprol; 2008; 74(5):471-4. PubMed ID: 19052406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis.
    Green L; Sadoff W
    J Cutan Med Surg; 2002; 6(2):95-102. PubMed ID: 11992180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical safety of tazarotene in the treatment of plaque psoriasis.
    Marks R
    J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S25-32. PubMed ID: 9270553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mometasone and calcipotriol optimize the initial therapeutic effect of dithranol in chronic persistent psoriasis].
    Sander P; Stücker M; Hermes N; Hoffmann K; Altmeyer P
    Hautarzt; 1998 Apr; 49(4):291-4. PubMed ID: 9606629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis.
    Schiener R; Behrens-Williams SC; Pillekamp H; Kaskel P; Peter RU; Kerscher M
    Br J Dermatol; 2000 Dec; 143(6):1275-8. PubMed ID: 11122033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis.
    Krueger GG; Drake LA; Elias PM; Lowe NJ; Guzzo C; Weinstein GD; Lew-Kaya DA; Lue JC; Sefton J; Chandraratna RA
    Arch Dermatol; 1998 Jan; 134(1):57-60. PubMed ID: 9449910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis.
    Lebwohl MG; Breneman DL; Goffe BS; Grossman JR; Ling MR; Milbauer J; Pincus SH; Sibbald RG; Swinyer LJ; Weinstein GD; Lew-Kaya DA; Lue JC; Gibson JR; Sefton J
    J Am Acad Dermatol; 1998 Oct; 39(4 Pt 1):590-6. PubMed ID: 9777766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tazarotene gel: efficacy and safety in plaque psoriasis.
    Weinstein GD
    J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S33-8. PubMed ID: 9270554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor-selective retinoids for psoriasis: focus on tazarotene.
    Weindl G; Roeder A; Schäfer-Korting M; Schaller M; Korting HC
    Am J Clin Dermatol; 2006; 7(2):85-97. PubMed ID: 16605289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis.
    Koo JY; Martin D
    Int J Dermatol; 2001 Mar; 40(3):210-2. PubMed ID: 11422529
    [No Abstract]   [Full Text] [Related]  

  • 16. Tazarotene combination treatments in psoriasis.
    Guenther L
    J Am Acad Dermatol; 2000 Aug; 43(2 Pt 3):S36-42. PubMed ID: 10898828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis.
    Tzung TY; Wu JC; Hsu NJ; Chen YH; Ger LP
    Acta Derm Venereol; 2005; 85(3):236-9. PubMed ID: 16040409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study.
    Bowman PH; Maloney JE; Koo JY
    J Am Acad Dermatol; 2002 Jun; 46(6):907-13. PubMed ID: 12063489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periungual pyogenic granulomas due to topical tazarotene for nail psoriasis.
    Piraccini BM; Venturi M; Patrizi A
    G Ital Dermatol Venereol; 2014 Jun; 149(3):363-6. PubMed ID: 24819765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of topical tazarotene: a review.
    Talpur R; Cox K; Duvic M
    Expert Opin Drug Metab Toxicol; 2009 Feb; 5(2):195-210. PubMed ID: 20213916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.